What is Leerink Partnrs’ Estimate for ELDN FY2029 Earnings?

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Analysts at Leerink Partnrs issued their FY2029 EPS estimates for Eledon Pharmaceuticals in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share of ($0.50) for the year. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share.

A number of other equities research analysts have also weighed in on ELDN. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Eledon Pharmaceuticals in a report on Wednesday, November 20th. Guggenheim began coverage on Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They set a “buy” rating and a $9.00 price target on the stock.

Eledon Pharmaceuticals Trading Down 1.1 %

NASDAQ:ELDN opened at $4.70 on Friday. Eledon Pharmaceuticals has a twelve month low of $1.52 and a twelve month high of $5.54. The company has a market cap of $280.78 million, a PE ratio of -2.34 and a beta of 0.79. The company’s 50 day moving average is $4.40 and its two-hundred day moving average is $3.60.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02).

Institutional Trading of Eledon Pharmaceuticals

Several large investors have recently made changes to their positions in ELDN. Dimensional Fund Advisors LP acquired a new position in Eledon Pharmaceuticals during the second quarter valued at $80,000. Renaissance Technologies LLC lifted its holdings in shares of Eledon Pharmaceuticals by 57.1% in the 2nd quarter. Renaissance Technologies LLC now owns 136,773 shares of the company’s stock valued at $361,000 after buying an additional 49,704 shares during the period. Clarity Capital Partners LLC purchased a new stake in shares of Eledon Pharmaceuticals in the third quarter worth about $29,000. Geode Capital Management LLC grew its holdings in Eledon Pharmaceuticals by 9.7% during the third quarter. Geode Capital Management LLC now owns 378,058 shares of the company’s stock worth $942,000 after acquiring an additional 33,569 shares during the period. Finally, Kera Capital Partners Inc. purchased a new position in Eledon Pharmaceuticals during the fourth quarter valued at approximately $106,000. 56.77% of the stock is owned by hedge funds and other institutional investors.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).